Lilly shares slip after Bernie Sanders criticizes insulin prices

November 1, 2016

Makers of insulin became the latest target for Sen. Bernie Sanders, who has been going after pharmaceutical companies one by one over the issue of high U.S. drug prices.

Shares of Indianapolis-based Eli Lilly and Co. fell after Sanders, an independent lawmaker from Vermont, criticized the company and Novo Nordisk A/S over the price of insulin. Along with France’s Sanofi, they are among the world’s largest producers of the drugs, which are used by millions of diabetics.

“People are dying or getting sicker because they can’t afford their insulin,” Sanders tweeted Tuesday. “Just so Eli Lilly and Novo Nordisk can make outrageous profits.”

Eli Lilly stock declined as much as 2.7 percent Tuesday to its lowest price since April, but recovered most of that loss by the end of the day. Shares finished at $72.98, a decline of 1.2 percent on the day. Novo Nordisk shares closed down less than 1 percent.

Sanders is attacking insulin makers even as U.S. payers like insurers and pharmacy benefit managers have been pressuring drugmakers on the price of the therapies.

Last week, Novo Nordisk A/S, the world’s biggest maker of insulin, cut its long-term target for profit growth by half, citing pricing competition in the U.S. And Lilly reported disappointing third-quarter U.S. sales of Humalog insulin, its best-selling product, dragged down by a decline in net pricethe money a drugmaker gets once rebates and discounts are subtracted from the so-called list price.

Companies respond

“While the list price for Humalog has gone up, Lilly actually receives a lower average net price now than in 2009,” Greg Kueterman, a company spokesman, said in an email. Humalog’s net price dropped 24 percent in the U.S. last quarter, he said.

Novo Nordisk said in a statement that it’s trying to ensure that a majority of Americans can get its insulins for about $1 a day and is looking forward “to working with lawmakers and officials toward a more sustainable system.”

The list prices of the pen versions of Humalog and Novo Nordisk’s Novolog have increased dramatically since 2011—they doubled per milliliter each, according to data compiled by Bloomberg. Though rebates to payers have also risen, many families on high-deductible plans increasingly have to pay the full price of drugs before their health insurance kicks in. A 30-day pack of Humalog or Novolog can cost more than $500, according to drug-price tracker goodrx.com, though the amount of insulin taken varies widely by patient.

Sanders had sent shares of Ariad Pharmaceuticals Inc. plunging when he questioned the price of the company’s pill for rare blood cancers last month. He later followed the tweet up with a letter to the company requesting information about recent price hikes.


Recent Articles by Bloomberg News

Comments powered by Disqus